Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663657 | 1.00 | HSD11B1 (0.55) | HSD11B1CYP2C19ALDH1A1POLBHTT | |
| Hydrochloric Acid SCHEMBL6906622 | 0.85 | KMT2A (0.50) | HSD11B1ALDH1A1POLBKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL6655911 | 0.85 | KMT2A (0.50) | HSD11B1ALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL6657701 | 0.81 | CYP2D6 (0.47) | LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL6662534 | 0.81 | OPRM1 (0.44) | CYP2C19ALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL6908373 | 0.81 | CYP2D6 (0.47) | LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL6662527 | 0.81 | OPRM1 (0.44) | CYP2C19ALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL6908168 | 0.79 | L3MBTL1 (0.50) | — | |
| SCHEMBL6659429 | 0.79 | L3MBTL1 (0.50) | — | |
| SCHEMBL6662353 | 0.78 | DPP8 (0.50) | ALDH1A1LMNAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1441728-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | Vertex Pharmaceuticals Incorporated (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-09 | — | — | US | disclosed |
| WO-2003037338-A2 | MODULATORS OF THE CHOLESTEROL BIOSYNTHETIC PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1257544-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001058891-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | HSD11B1 4758/4885CYP2C19 4725/4885ALDH1A1 1047/4885 |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | SREBF2, SREBF1, CYP46A1 | HSD11B1 36/4885CYP2C19 2585/4885ALDH1A1 2371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.